Medicines Council still cautious about nevirapine
The fact that one dose may lead to the creation of an HI-virus resistant to Nevirapine is no reason in itself not to register the anti-AIDS drug, but there should be strict monitoring by the drug companies of this, according to Professor Helen Rees chairperson of the Medicines Control Council (MCC).




